BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 5, 2025
Home » Blogs » BioWorld Perspectives » Biotech’s White Knight (aka Serial Cheater) Gets Prison Time, Finally

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / SEC

Biotech’s White Knight (aka Serial Cheater) Gets Prison Time, Finally

May 3, 2013
By Lynn Yoffee

JIt’s been 16 years since I first reported in BioWorld Today that David Blech was charged with securities fraud. In April 1997, I reached him at his New York office a few days after his arraignment in a U.S. District Court. Though he wouldn’t comment on the case, he chided me repeatedly for using the word “arrested,” insisting that I tell our readers he “appeared voluntarily” for the arraignment, still worried about his reputation ‑ as if it wasn’t already rubbish.

Frankly, I’m satisfied he’s going to serve time. Angry that our judicial system can’t penalize him with a longer sentence given the repeated widespread impact his actions have had on our industry. Amazed at his gall to repeat his offenses. Unforgiving that he blames his bipolar disorder for his misdeeds.

Blech's troubles began in September 1994 when his investment boutique, D. Blech & Co., suffered a liquidity crisis as capital reserves dipped below federally regulated levels and ceased trading activities on Nasdaq. The news sent the stock prices of numerous Blech-financed biotech start-ups spiraling down in an already bear market. His company's portfolio of 11 biotech firms lost more than $168 million in market capitalization in one day.

Blech, who founded his investment firm in 1990, was touted as the financial "white knight" of biotech start-ups. Four years later when his empire crumbled, some of his brokers not only received rubber paychecks, but they also were left without even the most basic tools of the trade, including telephones. It was really sad.

His former brokers said he ran "a sleazy boiler room operation," pressuring them to get clients to buy newly issued shares in companies underwritten by Blech and urged them just as strongly to advise those clients not to sell if the price started rising.

As the years stretched on, it only got messier.

A Florida attorney for former D. Blech & Co. employees was sentenced to five months in prison for obstructing an SEC investigation in 1997. Lloyd Schwed, of Jupiter, Fla., pleaded guilty in November 1996 to withholding and agreeing to destroy tapes subpoenaed by the SEC. Schwed represented the 10 former brokers in complaints filed against Blech. The brokers were ultimately awarded hundreds of thousands of dollars in damages stemming from the collapse of Blech's business.

In 1997 he was charged with scheming to defraud Bear Sterns & Co., which provided clearing services for securities transactions made by Blech's brokerage firm. But the judge felt sorry for him and refused to accept a guilty plea when he learned Blech was on meds for manic-depression.

Too bad. Because he turned right around and did it again. Blech made major stock purchases in three companies in 1997 ‑ Gene-Medicine Inc., Escalon Medical Corp. and Homecom Communications Inc ‑ without having enough assets to pay for them.

Who would stop this guy? U.S. District Judge Colleen McMahon slammed the gavel down this week.

The Associated Press reported that McMahon repeatedly scolded Blech during sentencing, which includes four years plus $1.3 million forfeiture. She called him a "serial stock manipulator" because he committed the same crime four times even after being granted leniency when he swore he wouldn’t commit another crime. Hooray for a strong judge.

So, almost two decades since the troublemaking started, I say good riddance, David Blech.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 4, 2025.
  • Green molecules

    UK Biobank delivers largest metabolomics dataset of 500K profiles

    BioWorld Science
    It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing